These two peptides are gaining serious traction in the functional medicine and performance communitiesand for good reason
Ginsenoside Rg1, a key bioactive component of ginseng, shows significant potential for treating Non-alcoholic fatty liver disease (NAFLD), a condition with limited therapeutic options
Ipamorelin, the first selective growth hormone secretagogue[J]
This shapes our peptide protocols: Emphasis on performance, recovery, and cognitive enhancement, not just symptom relief Advanced biomarker tracking beyond standard labs Integration with training, nutrition, and lifestyle optimization Objective outcome measures (body composition, HRV, sleep metrics, performance data) 5